Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
While the biotech market sees a high demand for the chief medical officer role, one Massachusetts oncology player has deemed the role completely unnecessary.
Pfizer Chief Executive Officer Albert Bourla tapped Aamir Malik to serve as the company’s chief business innovation officer.
Funds will be used to advance the clinical development of Cardior’s lead program, CDR132L, an oligonucleotide-based ncRNA inhibitor targeting micro-RNA-132.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
Rubix Life Sciences has launched a dedicated therapeutics division to focus on infectious and neurodegenerative diseases.
The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.
Atavistik Bio is linking a deep understanding of metabolite-protein interactions and their potential to lead to novel drugs that will restore protein function in metabolic diseases and cancers.
With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.
The FDA has approved the use of the injectable drug KORSUVA in treating moderate to severe pruritus in adult patients undergoing hemodialysis for chronic kidney disease.